Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500317 | 0.87 | MEN1 (0.30) | ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL809243 | 0.77 | DGAT1 (0.40) | ALDH1A1MEN1KMT2A | |
| SCHEMBL27961271 | 0.76 | DGAT1 (0.34) | — | |
| SCHEMBL461078 | 0.76 | — | — | |
| SCHEMBL29674742 | 0.74 | DGAT1 (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5491676 | 0.74 | TSHR (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1144196 | 0.74 | — | — | |
| SCHEMBL3358751 | 0.74 | — | — | |
| SCHEMBL9516243 | 0.74 | — | — | |
| SCHEMBL1244565 | 0.72 | MEN1 (0.54) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773284-B | Synthesis method of visible light mediated dihydroisoxazole | 河南大学 | 2024-03-29 | — | — | CN | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0871896-B1 | A METHOD OF DETERMINING OXYGEN CONCENTRATION IN A SAMPLE | NYCOMED IMAGING AS (NO) | 2002-01-30 | — | — | EP | disclosed |
| US-6256527-B1 | Method for determining oxygen concentration | NYCOMED IMAGING AS (NO) | 2001-07-03 | — | — | US | disclosed |
| EP-0832054-B1 | HETEROCYCLIC METHYL FREE RADICALS AS IMAGE ENHANCING AGENTS | NYCOMED IMAGING AS (NO) | 2000-12-27 | — | — | EP | disclosed |
| US-6063360-A | USEFUL AS CONTRAST AGENT FOR OVERHAUSER MAGNETIC RESONACE IMAGING | NYCOMED IMAGING A/S (NO) | 2000-05-16 | — | — | US | disclosed |
| US-5728370-A | Free Radicals | NYCOMED IMAGING AS (NO) | 1998-03-17 | — | — | US | disclosed |
| US-5663360-A | REACTING 3,4-DIMETHOXYAMPHETAMINE WITH 3-CHLOROMANDELIC ACID | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 1997-09-02 | — | — | US | disclosed |
| WO-1997009633-A1 | A METHOD OF DETERMINING OXYGEN CONCENTRATION IN A SAMPLE | NYCOMED IMAGING A/S (NO) | 1997-03-13 | — | — | WO | disclosed |
| WO-1996039367-A1 | HETEROCYCLIC METHYL FREE RADICALS AS IMAGE ENHANCING AGENTS | NYCOMED IMAGING A/S (NO) | 1996-12-12 | — | — | WO | disclosed |
| EP-0035363-B1 | INDANE DERIVATIVES, METHODS OF THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | KEFALAS A/S (DK) | 1985-05-02 | — | — | EP | disclosed |
| US-4443448-A | ANALGESICS, ANTIDEPRESSANTS, NEUROLEPTICS | KEFALAS A/S (DK) | 1984-04-17 | — | — | US | disclosed |
| EP-0004134-B1 | BETA-LACTAM ANTIBACTERIAL AGENTS, THEIR PHARMACEUTICAL COMPOSITIONS AND PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1981-12-30 | — | — | EP | disclosed |
| EP-0035363-A1 | Indane derivatives, methods of their preparation and compositions containing them | KEFALAS A/S (DK) | 1981-09-09 | — | — | EP | disclosed |
| US-4252808-A | β-Lactam antibacterial agents, their use in pharmaceutical compositions, the process for their preparation and intermediates for use in that process | BEECHAM GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
| EP-0004134-A1 | Beta-lactam antibacterial agents, their pharmaceutical compositions and process for their preparation | BEECHAM GROUP PLC (GB) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | ALDH1A1 1975/4885LMNA 3991/4885CYP1A2 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.